Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Tangible Book Value per Share 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 20, 2024

Kalvista Pharmaceuticals Inc Tangible Book Value per Share 1 year YoY Change (%) is NA for the Trailing 12 Months (TTM) ending September 20, 2024. Tangible book value per share represents the shareholders' equity (tangible) minus goodwill and intangible assets divided by the weighted average number of outstanding shares. It provides the value of tangible assets per share owned by the shareholders. This ratio helps investors assess the tangible asset value relative to the number of shares outstanding. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends